T cell epitope mapping of secukinumab and ixekizumab in healthy donors

T cell epitope mapping of secukinumab and ixekizumab in healthy donors

Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab has also shown lower in vitro immunogenicity potential compared with other mo...

Full description

Bibliographic Details
Main Authors: Sebastian Spindeldreher, Anette Karle, Evelyne Correia, Maxime Tenon, Sascha Gottlieb, Thomas Huber, Bernard Maillere, Frank Kolbinger
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:mAbs
Subjects:
Secukinumab
ixekizumab
immunogenicity
in vitro
epitope mapping
T cell lines
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2019.1707418

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2019.1707418

Similar Items